Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Humanized antibodies for therapy.

M S Co1, C Queen

  • 1Protein Design Labs, Inc., Mountain View, California 94043.

Nature
|June 6, 1991
PubMed
Summary
This summary is machine-generated.

Protein engineering enables combining murine antibody binding sites with human antibody regions. These engineered antibodies offer significant therapeutic advantages.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Improved gas chromatography-mass spectrometry method for simultaneous identification and quantification of opiates in urine as propionyl and oxime derivatives.

Clinical chemistry·2001
Same author

Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.

Journal of molecular recognition : JMR·1999
Same author

Properties and pharmacokinetics of two humanized antibodies specific for L-selectin.

Immunotechnology : an international journal of immunological engineering·1999
Same author

A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes.

Nature biotechnology·1998
Same author

Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin.

Journal of immunology (Baltimore, Md. : 1950)·1998
Same journal

Daily briefing: 'Cyborg' cockroaches breathe underwater with printed suit.

Nature·2026
Same journal

China boosts prestigious grants for young scientists - will it ease competition?

Nature·2026
Same journal

Incoming US science academy chief vows to 'double down' on research.

Nature·2026
Same journal

Author Correction: Synthesis of enantioenriched atropisomers by biocatalytic deracemization.

Nature·2026
Same journal

Electrodeposited self-assembled molecules for perovskite photovoltaics.

Nature·2026
Same journal

Neutrino's nursery found: the 'Shadow Blaster'.

Nature·2026
See all related articles

Area of Science:

  • Biotechnology
  • Immunology
  • Protein Engineering

Background:

  • Murine antibodies are effective for research but can elicit immune responses in humans.
  • Human antibodies have reduced immunogenicity but may lack specific binding affinities.
  • Protein engineering offers a solution to combine the benefits of both murine and human antibody components.

Purpose of the Study:

  • To explore the therapeutic potential of engineered antibodies.
  • To investigate methods for combining murine antibody binding sites with human antibody regions.
  • To highlight the advantages of such chimeric antibodies for clinical applications.

Main Methods:

  • Utilizing advanced protein engineering techniques.
  • Combining specific murine antibody variable regions (binding sites) with human antibody constant and framework regions.

Related Experiment Videos

  • Characterizing the resulting chimeric antibodies for binding affinity, stability, and effector functions.

    • Main Results:

    • Successfully engineered antibodies with retained murine binding specificity.
    • Demonstrated reduced immunogenicity compared to fully murine antibodies.
    • Observed favorable pharmacokinetic and pharmacodynamic profiles.

    Conclusions:

    • Engineered antibodies combining murine binding sites and human regions represent a promising therapeutic strategy.
    • This approach overcomes limitations of xenogeneic antibodies, offering improved safety and efficacy.
    • Further development of these chimeric antibodies holds significant potential for various therapeutic applications.